Rosuvastatin suppresses platelet‑derived growth factor‑BB‑induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway Retraction in /10.3892/etm.2023.12299

Gan,Jianting; Li,Ping; Wang,Zhengdong; Chen,Jian; Liang,Xiangwen; Liu,Ming; Xie,Wenchao; Yin,Ruixing; Huang,Feng

doi:10.3892/etm.2013.1265

Rosuvastatin suppresses platelet‑derived growth factor‑BB‑induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway

Retraction in: /10.3892/etm.2023.12299

Authors:
- Jianting Gan
- Ping Li
- Zhengdong Wang
- Jian Chen
- Xiangwen Liang
- Ming Liu
- Wenchao Xie
- Ruixing Yin
- Feng Huang
View Affiliations

Affiliations: Department of Cardiology, Sixth Affiliated Hospital of Guangxi Medical University, Yulin, Guangxi 537000, P.R. China, Department of Cardiology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: August 20, 2013 https://doi.org/10.3892/etm.2013.1265
Pages: 899-903

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An imbalance in the proliferation and migration of vascular smooth muscle cells (VSMCs) is significant in the onset and progression of vascular diseases, including arteriosclerosis and restenosis subsequent to vein grafting or coronary intervention. Rosuvastatin, a selective inhibitor of hydroxymethylglutaryl coenzyme A (HMG‑CoA) reductase, has pharmacological properties including the ability to reduce low‑density lipoprotein‑cholesterol (LDL‑C) and very low‑density lipoprotein‑cholesterol (VLDL‑C) levels, slow atherosclerosis progression and improve coronary heart disease outcomes. However, little is known concerning the molecular mechanism by which rosuvastatin affects vascular cell dynamics. In this study, we studied the inhibitory role of rosuvastatin on platelet‑derived growth factor‑BB (PDGF‑BB)‑induced VSMC proliferation and migration, as well as the molecular mechanisms involved. MTT data showed that rosuvastatin markedly inhibited the proliferation of PDGF‑BB‑induced VSMCs in a time‑dependent manner. VSMCs are able to dedifferentiate into a proliferative phenotype in response to PDGF‑BB stimulation; however, rosuvastatin effectively attenuated this phenotype switching. Moreover, we also showed that rosuvastatin significantly suppressed PDGF‑BB‑induced VSMC migration, which may be a result of its inhibitory effect on the protein expression of matrix metalloproteinase‑2 (MMP2) and MMP9. Investigation into the molecular mechanisms involved revealed that rosuvastatin inhibited the mitogen‑activated protein kinase (MAPK) signaling pathway by downregulating extracellular signal‑regulated kinase (ERK) and p38 MAPK, although the phosphorylation level of c‑Jun N‑terminal kinase (c‑JNK) was not altered following rosuvastatin treatment. In conclusion, the present study showed that rosuvastatin suppressed PDGF‑BB‑induced VSMC proliferation and migration, indicating that rosuvastatin has the potential to become a promising therapeutic agent for the treatment of atherosclerosis and restenosis.

View Figures

View References

1.	Doran AC, Meller N and McNamara CA: Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 28:812–819. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Hao H, Gabbiani G and Bochaton-Piallat ML: Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol. 23:1510–1520. 2003. View Article : Google Scholar : PubMed/NCBI
3.	Obata JE, Nakamura T, Kitta Y, et al: In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-eluting stent to treat a long de novo coronary lesion with small distal vessel diameter. Catheter Cardiovasc Interv. Feb 4–2013.(Epub ahead of print).
4.	Mazurova VV, Sukhorukov OE and Zakharova OV: Comparing moderately late results of the application of stents coated with a medicinal antiproliferative agent for the treatment of patients with various forms of coronary heart disease: their efficacy and safety. Klin Med (Mosk). 90:30–35. 2012.(In Russian).
5.	Babapulle MN and Eisenberg MJ: Coated stents for the prevention of restenosis: part I. Circulation. 106:2734–2740. 2002. View Article : Google Scholar : PubMed/NCBI
6.	Zhao Y, Liu YX, Xie SL, Deng BQ, Wang JF and Nie RQ: Increased expression of granulocyte colony-stimulating factor mediates mesenchymal stem cells recruitment after vascular injury. Chin Med J (Engl). 124:4286–4292. 2011.PubMed/NCBI
7.	Niida T, Isoda K, Kitagaki M, et al: IκBNS regulates inter-leukin-6 production and inhibits neointimal formation after vascular injury in mice. Cardiovasc Res. 93:371–379. 2012.
8.	Park ES, Kang SI, Yoo KD, et al: Camptothecin inhibits platelet-derived growth factor-BB-induced proliferation of rat aortic vascular smooth muscle cells through inhibition of PI3K/Akt signaling pathway. Exp Cell Res. 319:982–991. 2013. View Article : Google Scholar
9.	Sun L, Zhao R, Zhang L, et al: Salvianolic acid A inhibits PDGF-BB induced vascular smooth muscle cell migration and proliferation while does not constrain endothelial cell proliferation and nitric oxide biosynthesis. Molecules. 17:3333–3347. 2012. View Article : Google Scholar : PubMed/NCBI
10.	Sohda T, Iwata K, Hirano G, et al: 3-Hydroxyl-3-methylglut aryl-coenzyme A reductase is up regulated in hepatocellular carcinoma associated with paraneoplastic hypercholesterolemia. Med Mol Morphol. April 3–2013.PubMed/NCBI
11.	DiNicolantonio JJ, Lavie CJ, Serebruany VL and O’Keefe JH: Statin wars: the heavyweight match - atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med. 125:7–16. 2013. View Article : Google Scholar : PubMed/NCBI
12.	Abel T and Fehér J: Role of rosuvastatin in current lipid-lowering therapy. Orv Hetil. 151:1424–1428. 2010.(In Hungarian).
13.	Waters DD: Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. J Cardiol. 55:155–162. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Zhu L, Hao Y, Guan H, Cui C, Tian S, Yang D, Wang X, Zhang S, Wang L and Jiang H: Effect of sinomenine on vascular smooth muscle cell dedifferentiation and neointima formation after vascular injury in mice. Mol Cell Biochem. 373:53–62. 2013. View Article : Google Scholar : PubMed/NCBI
15.	Iida M, Tanabe K, Matsushima-Nishiwaki R, Kozawa O and Iida H: Adenosine monophosphate-activated protein kinase regulates platelet-derived growth factor-BB-induced vascular smooth muscle cell migration. Arch Biochem Biophys. 530:83–92. 2013. View Article : Google Scholar : PubMed/NCBI
16.	Li P, Liu Y, Yi B, et al: MicroRNA-638 is highly expressed in human vascular smooth muscle cells and inhibits PDGF-BB-induced cell proliferation and migration through targeting orphan nuclear receptor NOR1. Cardiovasc Res. 99:185–193. 2013. View Article : Google Scholar : PubMed/NCBI
17.	Park ES, Lee KP, Jung SH, et al: Compound K, an intestinal metabolite of ginsenosides, inhibits PDGF-BB-induced VSMC proliferation and migration through G1 arrest and attenuates neointimal hyperplasia after arterial injury. Atherosclerosis. 228:53–60. 2013. View Article : Google Scholar
18.	Yi N, Chen SY, Ma A, et al: Tunicamycin inhibits PDGF-BB-induced proliferation and migration of vascular smooth muscle cells through induction of HO-1. Anat Rec (Hoboken). 295:1462–1472. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Gao J, Ding F, Liu Q and Yao Y: Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem. 376:21–32. 2013. View Article : Google Scholar : PubMed/NCBI
20.	Mishra A, Srivastava A, Mittal T, Garg N and Mittal B: Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients. Clin Chim Acta. 413:1668–1674. 2012. View Article : Google Scholar : PubMed/NCBI
21.	Deatrick KB, Luke CE, Elfline MA, et al: The effect of matrix metalloproteinase 2 and matrix metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling. J Vasc Surg. Mar 9–2013.(Epub ahead of print).
22.	Halade GV, Jin YF and Lindsey ML: Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther. 139:32–40. 2013. View Article : Google Scholar : PubMed/NCBI
23.	Yang JL, Lin JH, Weng SW, et al: Crude extract of Euphorbia formosana inhibits the migration and invasion of DU145 human prostate cancer cells: The role of matrix metalloproteinase-2/9 inhibition via the MAPK signaling pathway. Mol Med Rep. 7:1403–1408. 2013.
24.	Santarpia L, Lippman SM and El-Naggar AK: Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
25.	Zhao Y, Lv M, Lin H, et al: ROCK1 induces ERK nuclear translocation in PDGF-BB-stimulated migration of rat vascular smooth muscle cells. IUBMB Life. 64:194–202. 2012. View Article : Google Scholar : PubMed/NCBI
26.	Zhu L, Guan H, Cui C, et al: Gastrodin inhibits cell proliferation in vascular smooth muscle cells and attenuates neointima formation in vivo. Int J Mol Med. 30:1034–1040. 2012.PubMed/NCBI